BIT225 crosses Blood -Brain Barrier

Terry Wilder interviews DR. Andrew Hill[his been working on clinical trails of drugs for HIV and HCV for 28 years.]. on Late Breaking abstract{covid19 epidemiology prevention treatment care from 2020 Aids Conference.

I like the part about the Blood -Brain Barrier


TW: I’m curious, because if a person doesn’t really recover from COVID-19, there’s this group of people called COVID-19 long-haulers; they’re complaining of brain fog and some other cognitive issues. So, I’m curious. Do these drugs actually pass "The blood-brain BARRIER" and maybe could help with that, as well?

AH: It’s possible. We are actually looking at long-term follow-up. So, we do have a 30-day post-trial evaluation to see whether people have any lingering symptoms, like—the classic one is just tired. These people are very tired afterwards. People can still have shortness of breath. There have been all sorts of different symptoms described. So, we are looking at that in the longer term.